Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD study of Leqselvi in healthy volunteers
NCT02777008Phase 1Completed
- Sponsor
- Concert Pharmaceuticals
- Start
- May 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of deuruxolitinib in alopecia areata (2 arms), sponsored by Concert Pharmaceuticals. Primary endpoints: Number of Participants with Adverse Events as a Measure of Safety and Tolerability at 24 hours and Measurement of CTP-543 exposure in plasma under fasted conditions at 24 hours. Started May 2016; status: completed.
02
Drugs
deuruxolitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT02777008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02777008.